These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2655907)

  • 21. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
    J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
    Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
    Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of short-term treatment with coenzyme A or sulodexide on plasma lipids in patients with hypertriglyceridemia (type IV) or mixed hyperlipemia (type IIb).
    Ghidini O; Zenari L; Guilarte N; Tessari R; Tomba A
    Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):390-6. PubMed ID: 3525431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes.
    Farvid MS; Siassi F; Jalali M; Hosseini M; Saadat N
    Diabetes Res Clin Pract; 2004 Jul; 65(1):21-8. PubMed ID: 15163474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
    Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
    Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
    Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
    Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multicenter study of the efficacy and tolerance of gemfibrozil and fenofibrate in the treatment of primary hyperlipoproteinemia].
    Manojlović D; Lepsanović L; Micić D; Sumarac M; Kendereski L; Popović V; Mićić J
    Srp Arh Celok Lek; 1991; 119(1-2):22-5. PubMed ID: 1788614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fenofibrate affects the compositions of lipoproteins.
    Goldberg AC; Schonfeld G; Anderson C; Dillingham MA
    Am J Med; 1987 Nov; 83(5B):60-5. PubMed ID: 3318455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
    Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Grundy SM; Knopp RH; Lasser NL; Mellies MJ; Palmer RH; Samuel P
    Arteriosclerosis; 1986; 6(6):670-8. PubMed ID: 3535757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.